ReviewGut2003
Pharmacogenomics: marshalling the human genome to individualise drug therapy.
Review in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic polymorphism of CYP2C19 in Maharashtrian population.European journal of epidemiology · 2007Pooled it
- Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.CNS drugs · 2008Trial
- Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.BMC genomic data · 2021Article
- Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.The pharmacogenomics journal · 2021Article
- Review
- Recent developments in genetic/genomic medicine.Clinical science (London, England : 1979) · 2019Review
- Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2019Review
- Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in a Chinese Tibetan population.Medicine · 2017Article
- State of Art of Cancer Pharmacogenomics in Latin American Populations.International journal of molecular sciences · 2017Review
- Implementing Precision Medicine: The Ethical Challenges.Trends in pharmacological sciences · 2017Review
- N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.The Indian journal of medical research · 2016Article
- Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.BMC medical informatics and decision making · 2015Article
- Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine.PloS one · 2015Article
- Role of pharmacogenomics in the treatment of tuberculosis: a review.Pharmacogenomics and personalized medicine · 2012Article
- Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- The application of genetics and genomics to cancer prevention.Seminars in oncology · 2010Review
- Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.International journal of medical sciences · 2010Article
- New pathways for alimentary mucositis.Journal of oncology · 2008Article
- Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.Molecular diagnosis & therapy · 2007Review
- Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.British journal of pharmacology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Pharmacogenomics aims to identify the inherited basis for interindividual differences in drug response, and translate this to molecular diagnostics that can be used to individualise drug therapy. This review uses a number of published examples of inherited differences in drug metabolising enzymes, drug transporters, and drug targets (for example, receptors) to illustrate the potential importance of inheritance in determining the efficacy and toxicity of medications in humans. It seems that this field is at the early stages of developing a powerful set of molecular diagnostics that will have profound utility in optimising drug therapy for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.